Achieving post-percutaneous coronary intervention low-density lipoprotein-cholesterol goals: Science versus reality

World Health Organization. Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: WHO, 2009.

Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG) and ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205.

Ference BA Ginsberg HN Graham I , et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459–2472.

Sabatine MS Giugliano RP Keech AC , et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Brener SJ Tarantini G Leon MB , et al. Cardiovascular and noncardiovascular death after percutaneous coronary intervention: Insights from 32 882 patients enrolled in 21 randomized trials. Circ Cardiovasc Interv 2018; 11: e006488.

Harris DE Lacey A Akbari A , et al. Achievement of European guideline-recommended lipid levels post percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol. Epub ahead of print 31 March 2020. DOI: 10.1177/2047487320914115.

Gitt AK Lautsch D Ferrieres J , et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266: 158–166.

De Backer G Jankowski P Kotseva K , et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285: 135–146.

Zafrir B Saliba W Jaffe R , et al. Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery. Eur J Prev Cardiol 2019; 26: 401–408.

Wang Y Yan BP Tomlinson B , et al. Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. Eur J Prev Cardiol 2019; 26: 1496–1506.

Nielsen SF Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: A nationwide prospective cohort study. Eur Heart J 2016; 37: 908–916.

Cohen JD Aspry KE Brown AS , et al. Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop. J Clin Lipidol 2013; 7: 573–609.

Chow CK Redfern J Hillis GS , et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: A randomized clinical trial. JAMA 2015; 314: 1255–1263.

Cannon CP Khan I Klimchak AC , et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol 2017; 2: 959–966.

Ray KK Wright RS Kallend D , et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. New Engl J Med. Epub ahead of print 18 March 2020. DOI: 10.1056/NEJMoa1912387.

Ray KK Bays HE Catapano AL , et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380: 1022–1032.

Ference BA Graham I Tokgozoglu L , et al. Reprint of: Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol 2018; 72: 2980–2995.